JP2022513308A5 - - Google Patents

Info

Publication number
JP2022513308A5
JP2022513308A5 JP2021536661A JP2021536661A JP2022513308A5 JP 2022513308 A5 JP2022513308 A5 JP 2022513308A5 JP 2021536661 A JP2021536661 A JP 2021536661A JP 2021536661 A JP2021536661 A JP 2021536661A JP 2022513308 A5 JP2022513308 A5 JP 2022513308A5
Authority
JP
Japan
Prior art keywords
polynucleotide
polypeptide
vector
seq
ascl1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021536661A
Other languages
English (en)
Japanese (ja)
Other versions
JP7450945B2 (ja
JP2022513308A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049150 external-priority patent/WO2020047467A2/en
Publication of JP2022513308A publication Critical patent/JP2022513308A/ja
Publication of JP2022513308A5 publication Critical patent/JP2022513308A5/ja
Priority to JP2023188492A priority Critical patent/JP2024001344A/ja
Application granted granted Critical
Publication of JP7450945B2 publication Critical patent/JP7450945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021536661A 2018-08-30 2019-08-30 ミオカルディンおよびascl1を用いた心細胞リプログラミング Active JP7450945B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023188492A JP2024001344A (ja) 2018-08-30 2023-11-02 ミオカルディンおよびascl1を用いた心細胞リプログラミング

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862725168P 2018-08-30 2018-08-30
US62/725,168 2018-08-30
US201962788479P 2019-01-04 2019-01-04
US62/788,479 2019-01-04
US201962852746P 2019-05-24 2019-05-24
US62/852,746 2019-05-24
PCT/US2019/049150 WO2020047467A2 (en) 2018-08-30 2019-08-30 Cardiac cell reprogramming with myocardin and ascl1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023188492A Division JP2024001344A (ja) 2018-08-30 2023-11-02 ミオカルディンおよびascl1を用いた心細胞リプログラミング

Publications (3)

Publication Number Publication Date
JP2022513308A JP2022513308A (ja) 2022-02-07
JP2022513308A5 true JP2022513308A5 (cg-RX-API-DMAC7.html) 2023-04-18
JP7450945B2 JP7450945B2 (ja) 2024-03-18

Family

ID=69643073

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021536661A Active JP7450945B2 (ja) 2018-08-30 2019-08-30 ミオカルディンおよびascl1を用いた心細胞リプログラミング
JP2023188492A Pending JP2024001344A (ja) 2018-08-30 2023-11-02 ミオカルディンおよびascl1を用いた心細胞リプログラミング

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023188492A Pending JP2024001344A (ja) 2018-08-30 2023-11-02 ミオカルディンおよびascl1を用いた心細胞リプログラミング

Country Status (11)

Country Link
US (4) US11015211B2 (cg-RX-API-DMAC7.html)
EP (1) EP3843774A4 (cg-RX-API-DMAC7.html)
JP (2) JP7450945B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210102870A (cg-RX-API-DMAC7.html)
CN (1) CN113164556A (cg-RX-API-DMAC7.html)
AU (2) AU2019333315B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021003897A2 (cg-RX-API-DMAC7.html)
CA (1) CA3111076A1 (cg-RX-API-DMAC7.html)
IL (1) IL281145A (cg-RX-API-DMAC7.html)
SG (1) SG11202102058UA (cg-RX-API-DMAC7.html)
WO (1) WO2020047467A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571704A (en) * 2018-02-22 2019-09-11 Georg August Univ Gottingen Stiftung Offentlichen Rechts Univer Sitatsmedzin Goettingen Prevention or treatment of cardiac arrhytmia and sudden cardiac death
KR20210102870A (ko) 2018-08-30 2021-08-20 테나야 테라퓨틱스, 인코포레이티드 미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
CN114450411A (zh) 2019-04-01 2022-05-06 特纳亚治疗股份有限公司 具有工程化衣壳的腺相关病毒
EP3997226A1 (en) * 2019-07-11 2022-05-18 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with micrornas and other factors
WO2021142267A1 (en) * 2020-01-08 2021-07-15 Scarpmap Llc Methods and computing system for processing ultrasound image to determine health of subdermal tissue
CN116249768A (zh) * 2020-07-29 2023-06-09 南京昕瑞再生医药科技有限公司 通过重编程产生心肌细胞的方法
JP7415042B2 (ja) 2020-10-09 2024-01-16 テナヤ セラピューティクス, インコーポレイテッド プラコフィリン2遺伝子治療の方法および組成物
EP4298215A1 (en) * 2021-02-25 2024-01-03 Tenaya Therapeutics, Inc. Enhancer sequences specific for cardiac fibroblasts and methods of use thereof
TW202317768A (zh) 2021-07-08 2023-05-01 美商特納亞治療股份有限公司 用於基因療法的優化表現卡匣
KR102902484B1 (ko) * 2022-11-25 2025-12-22 고려대학교 산학협력단 방사선 치료에 의하여 손상된 근육 재생을 위한 고기능성 세포 치료제 조성물
WO2024184781A1 (en) 2023-03-03 2024-09-12 Universitat Heidelberg Engineered aav capsids
CN117547621A (zh) * 2023-11-13 2024-02-13 苏州大学附属第二医院 激活gata5和isl1在心肌梗死后心脏损伤修复中的应用
CN121591917B (zh) * 2026-01-29 2026-05-26 广州医科大学 一种嵌合多肽、相关生物材料及其在诱导心肌细胞中的应用

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US7070994B2 (en) 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1994007529A1 (en) 1992-09-25 1994-04-14 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
FR2751345B1 (fr) 1996-07-16 1998-09-18 Univ Paris Curie Lignees d'encapsidation hautement productrices
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US6306434B1 (en) 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6254890B1 (en) 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US6984517B1 (en) 1998-05-28 2006-01-10 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector and uses thereof
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
WO2000073423A1 (en) 1999-06-01 2000-12-07 Chugai Seiyaku Kabushiki Kaisha Packaging cell
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
ATE324321T1 (de) 2000-08-31 2006-05-15 Edwin Lundgren Steuervorrichtung für einen lenkdrachen an einem boot
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
CA2432278A1 (en) * 2000-12-21 2002-08-08 Board Of Regents, The University Of Texas System Methods and compositions relating to cardiac-specific nuclear regulatory factors
US6962798B2 (en) * 2000-12-21 2005-11-08 Board Of Regents, The University Of Texas System Methods and compositions relating to a cardiac-specific nuclear regulatory factor
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
AU2002330714A1 (en) * 2001-05-30 2003-01-02 Biomedical Center In silico screening for phenotype-associated expressed sequences
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
EP1463805B1 (en) 2001-12-17 2014-10-22 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
US8105652B2 (en) 2002-10-24 2012-01-31 Massachusetts Institute Of Technology Methods of making decomposable thin films of polyelectrolytes and uses thereof
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
JP4553355B2 (ja) 2004-10-04 2010-09-29 富士フイルム株式会社 トリパノソーマ原虫寄生感染症の予防又は治療用医薬組成物
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
WO2006127980A2 (en) 2005-05-25 2006-11-30 The Regents Of The University Of California Optimized core promoters and uses therefor
DK2002003T3 (en) 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
WO2006138380A2 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
DE102005035527A1 (de) 2005-07-26 2007-02-08 Basf Ag Verwendung von Tetrahydrobenzoxazinen als Stabilisatoren
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
CA2634046A1 (en) 2005-12-12 2007-06-21 The University Of North Carolina At Chapel Hill Micrornas that regulate muscle cell proliferation and differentiation
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US7867484B2 (en) 2006-01-27 2011-01-11 University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
WO2008016391A2 (en) 2006-01-31 2008-02-07 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
EP2046266A4 (en) 2006-07-21 2009-11-04 Massachusetts Inst Technology ENDMODICIFIED POLY (BETA AMINO ESTER) AND ITS USE
US20100303723A1 (en) 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
CA2694928A1 (en) 2007-07-31 2009-02-05 Board Of Regents, The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
WO2009110939A2 (en) 2007-12-10 2009-09-11 Massachusetts Institute Of Technology Drug delivery system for pharmaceuticals and radiation
CN102083980A (zh) 2008-02-21 2011-06-01 得克萨斯系统大学董事会 调节平滑肌增殖和分化的微小rna及其用途
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2010042555A2 (en) 2008-10-06 2010-04-15 The Brigham And Women's Hospital, Inc. Particles with multiple functionalized surface domains
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US9532956B2 (en) 2009-04-18 2017-01-03 Massachusetts Institute Of Technology PH sensitive biodegradable polymeric particles for drug delivery
US9169494B2 (en) 2010-01-12 2015-10-27 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
JP5988961B2 (ja) 2010-04-28 2016-09-07 ザ ジェイ. デヴィッド グラッドストーン インスティテューツ 心筋細胞を発生させるための方法
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
EP2591095B1 (en) 2010-07-08 2016-04-27 Duke University Direct reprogramming of cells to cardiac myocyte fate
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9017661B2 (en) 2011-02-22 2015-04-28 The Board Of Regents Of The University Of Texas System Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
CA2837322C (en) 2011-05-26 2023-03-21 University Of Washington Cell and gene based methods to improve cardiac function
US9828585B2 (en) 2011-08-30 2017-11-28 The J. David Gladstone Instututes Methods for generating cardiomyocytes
US8935819B1 (en) 2011-09-22 2015-01-20 Rick Hartley Mattress foundations, kits and related methods
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
CA2859205A1 (en) 2011-12-16 2013-06-20 Massachusetts Institute Of Technology Alpha-aminoamidine polymers and uses thereof
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2841056A4 (en) 2012-04-23 2015-09-16 Massachusetts Inst Technology STABLE LAYER COATED PARTICLES
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
EP2970966A4 (en) 2013-03-15 2016-10-26 Univ North Carolina SYNTHETIC ADENOASSOZED VIRUS INVERTED REPEAT SEQUENCES
JP6726824B2 (ja) * 2013-07-17 2020-07-22 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 効率的な遺伝子送達用途のための非毒性hsvベクター及びその製造のための補完細胞
CN103451284B (zh) * 2013-08-22 2015-03-18 中国科学院生物物理研究所 一组人类心肌细胞的新型分子标记物及其应用
EP3060649A4 (en) 2013-10-23 2017-07-12 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Reprogramming cardiomyocytes with one transcription factor
WO2016115543A2 (en) 2015-01-16 2016-07-21 University Of Washington Novel micro-dystrophins and related methods of use
US10648000B2 (en) 2015-02-16 2020-05-12 University Of Florida Research Foundation, Incorporated rAAV vector compositions, methods for targeting vascular endothelial cells and use in treatment of type I diabetes
US9885018B1 (en) 2015-03-16 2018-02-06 The Regents Of The University Of Colorado, A Body Corporate High efficiency reprogramming of fibroblasts into cardiomyocytes
JP6836999B2 (ja) 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California アデノ随伴ウイルス変異体及びその使用方法
BR112018070255A2 (pt) 2016-03-30 2019-01-29 The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone reprogramação cardíaca direta melhorada.
WO2018222503A1 (en) 2017-05-31 2018-12-06 The Regents Of The University Of California Adeno-associated virus with variant capsid and methods of use thereof
US20210180023A1 (en) 2017-08-15 2021-06-17 The Board Of Regents Of The University Of Texas System Cardiac repair by reprogramming of adult cardiac fibroblasts into cardiomyocytes
DK3684423T5 (da) 2017-09-20 2024-08-26 4D Molecular Therapeutics Inc Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
KR20210102870A (ko) 2018-08-30 2021-08-20 테나야 테라퓨틱스, 인코포레이티드 미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
US20200405824A1 (en) 2019-06-26 2020-12-31 University Of Washington Use of ribonucleotide reductase alone or in combination with micro-dystrophin to treat duchenne muscular dystrophy striated muscle disease
EP3997226A1 (en) 2019-07-11 2022-05-18 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with micrornas and other factors
CN115552022A (zh) 2020-03-02 2022-12-30 特纳亚治疗股份有限公司 由心肌细胞表达的微rna控制的基因载体

Similar Documents

Publication Publication Date Title
JP2023070682A5 (cg-RX-API-DMAC7.html)
CN113316639A (zh) 用于治疗庞贝氏病的治疗性腺相关病毒
JP2020518268A5 (cg-RX-API-DMAC7.html)
JP2022522996A5 (cg-RX-API-DMAC7.html)
US7655467B2 (en) Compositions and methods for systemic nucleic acid sequence delivery
RU2005136233A (ru) Выделенный рекомбинантный вирус гриппа и способы его получения
MX2023012410A (es) Metodos para tratar enfermedades oculares usando variantes de aav2 que codifican aflibercept.
JP2015501156A5 (cg-RX-API-DMAC7.html)
KR20180102172A (ko) 다논병 및 다른 자가포식 장애의 치료 방법
EA003086B1 (ru) ПОЛИПЕПТИДЫ LAG-3V1, LAG-3V2 И LAG-3V3 И КОДИРУЮЩИЕ ИХ кДНК
JP2024503091A5 (cg-RX-API-DMAC7.html)
JP2015521465A5 (cg-RX-API-DMAC7.html)
MX2022002961A (es) Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept.
MX2024009478A (es) Métodos para tratar enfermedades neovasculares oculares con variantes de aav2 que codifican aflibercept
JPWO2020218419A5 (cg-RX-API-DMAC7.html)
JP2023539247A5 (cg-RX-API-DMAC7.html)
JP2025107171A (ja) 心臓保護的活性のあるタンパク質
CN114934070B (zh) 间充质干细胞及其抗炎应用
MX2022002960A (es) Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept.
JP2024515902A5 (cg-RX-API-DMAC7.html)
CN102127546B (zh) 一种骨骼肌特异性actin启动子及其应用
WO2023045996A1 (zh) 一种用于糖代谢相关疾病基因治疗的核酸构建体
JP2003524389A5 (cg-RX-API-DMAC7.html)
WO2025112194A1 (zh) 一种调控糖脂代谢和抗衰老的双功能重组蛋白gik及其制备方法
IL315711A (en) Therapeutic adeno-associated virus using codon optimized nucleic acid encoding alpha-glucosidase (gaa) for treating pompe disease, with signal peptide modifications